Professor Xia Jianchuan, current director of the Biotherapy Center, doctor of medicine, doctoral supervisor, chairman of the Chinese Society of Medical Bioimmunology, chairman of the Cell Therapy Quality Control and Research Professional Committee of the Chinese Medical Quality Management Association, chairman of the Guangdong Society of Cell Biology, Chairman of the Biotherapy Professional Committee of Guangdong Anti-Cancer Association, Chairman of the Guangdong Immunological and Biological Therapy Professional Committee, Executive Director of China Medical Biotechnology Association, Standing Member of China Biotherapeutic Clinical Application Professional Committee, National Food and Drug Administration New Drug Review Expert , The leader of the immunology and genetic research group of the National Key Laboratory of Oncology in South China. Member of the editorial board of American "Cancer Letter" magazine, executive editor of "Cancer" magazine, expert reviewer for key projects of the National Natural Science Foundation of China and Guangdong Provincial Natural Science Foundation.

Professor Xia Jianchuan graduated from Harbin Medical University in 1998 with a doctor of medicine; from 1998 to 2000, he was engaged in postdoctoral research in the Affiliated Tumor Hospital of Sun Yat-sen Medical University; from 2000 to 2003, he was engaged in tumor immunotherapy at Harvard University Dana-Farber Cancer Institute And tumor vaccine research. During this period, it was confirmed for the first time that the DC/tumor fusion cell vaccine can induce spontaneous breast cancer transgenic mice to produce an anti-tumor immune response, laying the foundation for the application of the DC/tumor fusion cell vaccine in the clinical treatment of tumors. The research results were published in the United States Journal of Immunology (J Immunol 2003 Feb 15; 170 (4): 1980-1986; J Immunol, 2004, 172: 7848-7858; Immunology. 2003 Jun; 109(2): 300-7), June 2003 Returned to China in September, using the advanced somatic cell immunotherapy technology learned abroad to actively carry out basic and clinical application research on tumor somatic immunotherapy, and established the first domestic somatic cell preparation technology operating specifications, somatic cell clinical application safety testing standards and The clinical application standard of somatic immunotherapy has taken an important step on the road to standardization of somatic immunotherapy, and has made important contributions to the safe and effective application of somatic immunotherapy for tumors in the clinical treatment process.

In recent years, he has presided over and participated in a number of major national, provincial and ministerial clinical application research projects, actively carried out basic and clinical application research on tumor etiology and tumor somatic immunotherapy, and published SCI in the field of tumor etiology and tumor somatic immunotherapy More than 50 research papers have been collected. Editor-in-chief of the first domestic textbook "Basic and Clinical Application of Tumor Biotherapy" (published by China Science and Technology Press in August 2011); as an associate editor, he wrote the monograph "Principles of Individualized Medicine" (by People's Medical Publishing House, 2013) Published monthly); participated in the compilation of the undergraduate textbook "Clinical Oncology" for medical colleges and universities and the postgraduate textbook "Clinical Oncology" for medical colleges and universities. Obtained two national invention patents (a technology for separation and purification of human tumor cells. National invention patent number: ZL 03146933.7; OK-432 combined with IFN-γ stimulates the maturation of type I polarized dendritic cells and enhances the anti-tumor immune response. National invention Patent number: 20131004940.6). He has won the second prize of the Provincial Government's Science and Technology Progress Award, and in 2008, the first Guangzhou New Overseas Chinese Students Returned to the Country for Entrepreneurship Contribution Award, and enjoyed special government allowances.



Awards:
      (1) The second prize of Provincial Science and Technology Progress Award;

(2) The first prize of Science and Technology Progress Award of Provincial Education Commission;

(3) In 2008, the first Guangzhou New Overseas Chinese Students Returned to China and Contributed to Entrepreneurship



focus on:

Editor-in-chief "Basic and Clinical Application of Tumor Biotherapy", Beijing, Science Press, 2011;

Associate editor of the monograph "Principles of Individualized Medicine" (published by People's Medical Publishing House in January 2013);

Editor-in-chief "Tumor Biotherapy", Jiangsu Phoenix Science and Technology Press, October 2014;



Obtained a patent:
      (1) Method for separation and purification of human tumor cells Patent number: ZL 03146933.7

(2) Composition and method for stimulating the maturation of dendritic cells Patent No.: ZL 20131004940.6